A recent study found no significant difference in the outcome for patients who received carotid artery stenting (CAS) at more than 30 days post-transient ischemic attack (TIA) or stroke versus those who received CAS at 30 ...
Nov 14, 2011
0
0
Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) ...
Nov 9, 2011
0
0
A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of ...
Nov 9, 2011
0
0
The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis ...
Nov 9, 2011
0
0
In a first-of-its-kind study, researchers from Mount Sinai School of Medicine have discovered several gene variants contributing to early stent thrombosis (ST), a devastating and often deadly complication after coronary stent ...
Oct 25, 2011
0
0
People who suffer from acute stroke or Transient Ischaemic Attack (TIA, a mini stroke) could get better treatment in the future thanks to the expansion of a large clinical trial of a new combination of drugs led by researchers ...
Oct 17, 2011
0
0
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of ...
Sep 26, 2011
0
0
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who ...
Sep 20, 2011
1
0
The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...
Sep 12, 2011
0
0
A randomised multicentre open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy is no better than six months ...
Aug 30, 2011
0
0
